Cargando…
Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?
Padron et al.(1) studied the combination of chemotherapy (gemcitabine and nab-paclitaxel) with either an anti-PD1 (nivolumab) or an anti-CD40 (sotigalimab) antibody in metastatic pancreatic cancer. They showed clinical benefit in individuals with unique biomarkers for each treatment combination
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589119/ https://www.ncbi.nlm.nih.gov/pubmed/36260984 http://dx.doi.org/10.1016/j.xcrm.2022.100788 |
| Sumario: | Padron et al.(1) studied the combination of chemotherapy (gemcitabine and nab-paclitaxel) with either an anti-PD1 (nivolumab) or an anti-CD40 (sotigalimab) antibody in metastatic pancreatic cancer. They showed clinical benefit in individuals with unique biomarkers for each treatment combination |
|---|